Cannabinoid Receptor (CB1) Agonist Treatment in Severe Chronic Anorexia Nervosa
Status:
Completed
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
A pilot study designed to reveal the effects of Marinol / dronabinol, a CB 1 agonist.
Primary end point: To estimate weight gain and EDI scores in patients receiving Marinol
compared to placebo
Secondary end points: Motor and inner restlessness and hormonal changes during the treatment.